With the risk of diversion potentially greater than it was before the pandemic, these data should be viewed as a warning sign.
Tom Knight, CEO, Invistics
Advertisement
Articles by Tom Knight, CEO, Invistics
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
2
Gaps Between Expectations and Effects on Long COVID Contribute to Trust in Vaccines
3
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
4
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
5
